---
document_datetime: 2024-06-28 13:19:58
document_pages: 30
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/neulasta-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
document_name: neulasta-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
version: success
processing_time: 17.5713511
conversion_datetime: 2025-12-28 12:55:01.224807
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Neulasta

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                                                                                            | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| IG/1743              | A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release) | 28/06/2024                          |                                             | Annex II                         |           |
| IB/0123              | C.I.11.z - Introduction of, or change(s) to, the                                                                                                                                                 | 17/10/2023                          | n/a                                         |                                  |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|                    | obligations and conditions of a marketing authorisation, including the RMP - Other variation                                                                                                                                                                                                                                                                                                                                                                                 |            |            |                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
|--------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0121            | Submission of the final report from PASS study 20170701 listed as a category 3 study in the RMP. This is a cross-sectional survey study to assess the effectiveness of the Neulasta Patient Alert Card and to measure medication errors related to the use of the Neulasta On-Body Injector. The RMP version 9.0 was accepted. C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority | 06/07/2023 | n/a        |                        | This variation concerns the final study report of the category 3 post-authorization safety study (PASS) 20170701 to evaluate the effectiveness of the patient alert card and to measure medication errors related to the use of the Neulasta On-Body Injector (OBI). Of the 62 respondents who completed all relevant sections of the study questionnaire, the median composite endpoint for awareness and behavioural intent reached the predefined cut-off level. The questionnaire design did not allow estimation of medication errors with the OBI in clinical practice. However, as concurrently to this procedure the OBI was withdrawn from the European market, no further regulatory actions were considered necessary following the results of this study. |
| IB/0122            | B.II.e.z - Change in container closure system of the Finished Product - Other variation                                                                                                                                                                                                                                                                                                                                                                                      | 27/06/2023 |            | SmPC, Labelling and PL |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| PSUSA/2326/ 202201 | Periodic Safety Update EU Single assessment - pegfilgrastim                                                                                                                                                                                                                                                                                                                                                                                                                  | 29/09/2022 | n/a        |                        | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| IB/0120            | B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS                                                                                                                                                                                                                                                                                                                                                             | 15/09/2022 | n/a        |                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| II/0116            | Submission of the final report from study 20170701 listed as a category 3 study in the RMP (MEA-060.5). This is an observational study to assess the effectiveness of the Neulasta patient alert card and                                                                                                                                                                                                                                                                    | 02/12/2021 | 16/12/2022 | PL                     | Package leaflet (Patient instructions for use) new text: The on-body injector can be worn in a shower. After showering, check the on-body injector to ensure it has not become dislodged.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |

<div style=\"page-break-after: always\"></div>

|           | to measure medication errors related to the use of the On-Body Injector. Data provided justified additional activity to be included in the Patient Instruction for use in the package leaflet. The MAH took the occasion to amend local representative details for Malta, Germany and to align the PI to the recent QRD template version 10.2. The RMP version 8.0 has also been submitted. C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority   |            |     | For more information, please refer to the Summary of Product Characteristics.   |
|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|---------------------------------------------------------------------------------|
| II/0117   | B.I.b.2.d - Change in test procedure for AS or starting material/reagent/intermediate - Substantial change to or replacement of a biological/immunological/immunochemical test method or a method using a biological reagent for a biological AS                                                                                                                                                                                                                                                                                            | 18/11/2021 | n/a |                                                                                 |
| IB/0118/G | This was an application for a group of variations. B.I.z - Quality change - Active substance - Other variation B.I.a.1.k - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - New storage site of MCB and/or WCB B.I.a.1.k - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - New storage site of MCB and/or WCB                                                                                                                                              | 26/10/2021 | n/a |                                                                                 |

<div style=\"page-break-after: always\"></div>

| IB/0115   | B.II.z - Quality change - Finished product - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 04/05/2021   | n/a        |                       |                                                                                                                                                                                                                                                                 |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|-----------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0114   | Update of section 6.6 of the SmPC in order to add a new warning that the medicine should be allowed to reach room temperature before use, based on cumulative reviews of post-marketing reports of medication errors with the on-body injector and in response to the PAM EMEA/H/C/000420/MEA/060.3. The MAH also took the opportunity to introduce an editorial change in section 4.4 of the SmPC. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                                                                                                                                                        | 11/03/2021   | 13/12/2021 | SmPC                  | Allow the pre-filled syringe for manual administration and pre-filled syringe co-packed with the on-body injector (Onpro kit) for automatic administration to come to room temperature for 30 minutes before using the syringe.                                 |
| II/0113   | Submission of the final report from study 20160176 listed as a category 3 study in the RMP. This is a retrospective cohort study with primary outcome the time from index date to diagnosis of MDS or AML (safety). As a result, section 4.4 and 4.8 of the SmPC is updated to add a new warning on Myelodysplastic syndrome (MDS) and acute myeloid leukaemia (AML), and to add them in the list of adverse drug reactions (ADRs) with frequency uncommon; the Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to bring the PI in line with the latest QRD template version 10.1. C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission | 26/11/2020   | 13/12/2021 | SmPC, Annex II and PL | In the post-marketing observational study setting, myelodysplastic syndrome (MDS) and acute myeloid leukaemia (AML) have been associated with the use of pegfilgrastim in conjunction with chemotherapy and/or radiotherapy in breast and lung cancer patients. |

<div style=\"page-break-after: always\"></div>

|                    | of studies to the competent authority                                                                                                                                                                                                                                                                                                                                                                                                                          |            |            |             |                                                                                                                        |
|--------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|------------------------------------------------------------------------------------------------------------------------|
| IB/0112            | B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation                                                                                                                                                                                                                                                                                                                            | 27/02/2020 | n/a        |             |                                                                                                                        |
| IB/0111/G          | This was an application for a group of variations. B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non- significant specification parameter (e.g. deletion of an obsolete parameter) B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS                                                                        | 25/11/2019 | n/a        |             |                                                                                                                        |
| IA/0110/G          | This was an application for a group of variations. B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure | 22/11/2019 | n/a        |             |                                                                                                                        |
| PSUSA/2326/ 201901 | Periodic Safety Update EU Single assessment - pegfilgrastim                                                                                                                                                                                                                                                                                                                                                                                                    | 19/09/2019 | 22/11/2019 | SmPC and PL | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for |

<div style=\"page-break-after: always\"></div>

|           |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |            |            |             | PSUSA/2326/201901.   |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|----------------------|
| IA/0108   | B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non- significant specification parameter (e.g. deletion of an obsolete parameter)                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 04/04/2019 | n/a        |             |                      |
| IB/0107   | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 29/03/2019 | 22/11/2019 | SmPC and PL |                      |
| II/0099   | Submission of an updated RMP (version 6.2) in order to add study 20160176, a retrospective cohort study of female breast cancer patients aged 66 years and over selected from the US SEER-Medicare database to estimate the risk of acute myeloid leukemia/myelodysplastic syndrome for breast cancer patients, as a new Pharmacovigilance activity (category 3). In addition, the MAH submitted the draft protocol for study 20160176. C.I.11.b - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Implementation of change(s) which require to be further substantiated by new additional data to be submitted by the MAH | 14/03/2019 | n/a        |             |                      |
| IB/0105   | B.II.b.3.z - Change in the manufacturing process of the finished or intermediate product - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 04/10/2018 | n/a        |             |                      |
| IAIN/0106 | C.I.z - Changes (Safety/Efficacy) of Human and                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 13/09/2018 | 31/10/2018 | SmPC and PL |                      |

<div style=\"page-break-after: always\"></div>

|           | Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |            |            |             |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|
| IB/0103   | B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process                                                                                                                                                                                                                                                                                                                                                                                                                                               | 02/07/2018 | n/a        |             |
| IG/0946   | B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing                                                                                                                                                                                                                                                                                                                                             | 04/06/2018 | 31/10/2018 | PL          |
| IAIN/0101 | C.I.3.a - Change(s) in the SPC, Labelling or PL intended to implement the outcome of a procedure concerning PSUR or PASS or the outcome of the assessment done under A 45/46 - Implementation of wording agreed by the competent authority                                                                                                                                                                                                                                                                                                                                         | 17/05/2018 | 31/10/2018 | SmPC and PL |
| WS/1177/G | This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.I.a.1.e - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The change relates to a biological AS or a starting material [-] used in the manufacture of a biological/immunological product B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting | 26/04/2018 | n/a        |             |

<div style=\"page-break-after: always\"></div>

|           | material/intermediate                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |            |            |                                  |                    |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|--------------------|
| II/0093/G | This was an application for a group of variations. Update of sections 3, 4.2, 4.4, 4.8, 5.1, 6.4, 6.5, 6.6 and 8 of the SmPC. The Labelling, Package Leaflet and the RMP (version 4.2) are updated accordingly. In addition the Marketing authorisation holder (MAH) took the opportunity to update the list of local representatives in the Package Leaflet, to include some editorial changes and correct some typos throughout the product information, and to bring the product information in line with the latest QRD template version 10. B.II.e.5.c - Change in pack size of the finished product - Change in the fill weight/fill volume of sterile multidose (or single-dose, partial use) parenteral medicinal products, including biological/immunological medicinal products B.IV.1.a.3 - Change of a measuring or administration device - Addition or replacement of a device which is not an integrated part of the primary packaging - Spacer device for metered dose inhalers or other device which may have a significant impact on the | 22/02/2018 | 31/10/2018 | SmPC, Annex II, Labelling and PL | delivery of the AS |
| IG/0853   | B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 10/11/2017 | 19/02/2018 | Annex II and PL                  |                    |

<div style=\"page-break-after: always\"></div>

| WS/1159   | application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.I.a.2.c - Changes in the manufacturing process of the AS - The change refers to a [-] substance in the manufacture of a biological/immunological substance which may have a significant impact on the medicinal product and is not related to a protocol                                                                                                                                                                                                                                                                                                                                                                            | 06/07/2017   | n/a   | This was an   |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-------|---------------|
| IB/0096   | B.I.b.z - Change in control of the AS - Other                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 31/05/2017   | n/a   | variation     |
| WS/1099/G | This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.I.a.4.b - Change to in-process tests or limits applied during the manufacture of the AS - Addition of a new in-process test and limits B.I.a.4.e - Change to in-process tests or limits applied during the manufacture of the AS - Deletion of an in-process test which may have a significant effect on the overall quality of the AS B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non- significant specification parameter (e.g. deletion of an obsolete parameter) B.I.b.1.e - Change in the specification parameters | 18/05/2017   | n/a   |               |

<div style=\"page-break-after: always\"></div>

|           | and/or limits of an AS, starting material/intermediate/reagent - Deletion of a specification parameter which may have a significant effect on the overall quality of the AS and/or the FP B.I.d.1.c - Stability of AS - Change in the re-test period/storage period or storage conditions - Change to an approved stability protocol B.II.b.5.b - Change to in-process tests or limits applied during the manufacture of the finished product - Addition of a new test(s) and limits B.II.b.5.b - Change to in-process tests or limits applied during the manufacture of the finished product - Addition of a new test(s) and limits B.II.b.5.b - Change to in-process tests or limits applied during the manufacture of the finished product - Addition of a new test(s) and limits B.II.d.1.d - Change in the specification parameters and/or limits of the finished product - Deletion of a non-significant specification parameter B.II.d.1.f - Change in the specification parameters and/or limits of the finished product - Deletion of a specification parameter which may have a significant effect on the overall quality of the finished product B.II.d.3 - Variations related to the introduction of real-time release or parametric release in the manufacture of the finished product B.II.f.1.e - Stability of FP - Change to an approved   |            |            |                 |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------|
| IAIN/0094 | A.5.a - Administrative change - Change in the name and/or address of a manufacturer/importer responsible for batch release                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 10/03/2017 | 19/02/2018 | Annex II and PL |

<div style=\"page-break-after: always\"></div>

| WS/1022/G   | This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.I.a.4.e - Change to in-process tests or limits applied during the manufacture of the AS - Deletion of an in-process test which may have a significant effect on the overall quality of the AS   | 19/01/2017   | n/a   |
|-------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-------|

<div style=\"page-break-after: always\"></div>

|                    | changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate B.I.d.1.c - Stability of AS - Change in the re-test period/storage period or storage conditions - Change to an approved stability protocol                                  |            |     |                                   |
|--------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-----------------------------------|
| IA/0090            | A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                                                                              | 07/09/2016 | n/a |                                   |
| PSUSA/2326/ 201601 | Periodic Safety Update EU Single assessment - pegfilgrastim                                                                                                                                                                                                                                | 02/09/2016 | n/a | PRAC Recommendation - maintenance |
| IB/0089            | B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate                                                                               | 07/07/2016 | n/a |                                   |
| IB/0087            | B.II.g.5.c - Implementation of changes foreseen in an approved change management protocol - For a biological/immunological medicinal product                                                                                                                                               | 18/03/2016 | n/a |                                   |
| WS/0834            | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.II.g.5.c - Implementation of changes foreseen in an approved change management protocol - For a biological/immunological medicinal product | 10/12/2015 | n/a |                                   |

<div style=\"page-break-after: always\"></div>

| II/0085   | C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority                                                                                                                                                                                                              | 16/07/2015   | n/a        |             |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|-------------|
| II/0084   | C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                                                                                                                                                                                          | 21/05/2015   | 26/05/2016 | SmPC and PL |
| WS/0660   | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate | 26/03/2015   | n/a        |             |
| II/0082   | C.I.11.b - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Implementation of change(s) which require to be further substantiated by new additional data to be submitted by the MAH where significant assessment is required                                                             | 26/02/2015   | n/a        |             |
| II/0078   | Introduction of a Post Approval Change Management Protocol for the finished product B.II.g.2 - Introduction of a post approval change management protocol related to the finished product                                                                                                                                                                  | 25/09/2014   | n/a        |             |

<div style=\"page-break-after: always\"></div>

| IB/0081   | - Changes in the manufacturing process of AS - Minor change in the manufacturing process the AS                                                                                                                                                                                                                                           | 22/09/2014   | n/a        |             | B.I.a.2.a the of       |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|-------------|------------------------|
| IB/0080   | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                            | 15/08/2014   | 13/11/2014 | SmPC and PL |                        |
| N/0079    | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                          | 27/05/2014   | 13/11/2014 | PL          |                        |
| II/0076   | to add a site responsible for lot release testing of Neulasta finished product. B.II.b.2.b - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place for a biol/immunol product and any of the test methods at the site is a method | 22/05/2014   | n/a        |             | biol/immunol           |
| II/0075   | C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                                                                                                                                                                         | 22/05/2014   | 13/11/2014 | SmPC and PL |                        |
| IA/0077   | B.III.1.b.3 - Submission of a new/updated or deletion of Ph. Eur. TSE Certificate of Suitability - Updated certificate from an already approved manufacturer                                                                                                                                                                              | 13/05/2014   | n/a        |             |                        |
| II/0072   | change in manufacturing process of filgrastim the manufacturing process of                                                                                                                                                                                                                                                                | 23/01/2014   | n/a        |             | B.I.a.2.c - Changes in |

<div style=\"page-break-after: always\"></div>

|           | the AS - The change refers to a [-] substance in the manufacture of a biological/immunological substance which may have a significant impact on the medicinal product and is not related to a protocol                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |            |            |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                       |
|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IA/0074   | A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 09/12/2013 | n/a        |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| II/0070   | Update of section 4.6 of the SmPC with details of Amgen's pregnancy surveillance program (PSP) and lactation surveillance program (LSP) and section 4.9 on information on overdose. The Package Leaflet is updated accordingly. Amgen also addressed in this submission the Quality Review of Documents (QRD) groups comments on the SmPC, PL (including the instructions for use) and labelling made during the recently concluded procedure to introduce minor changes to the Automatic Needle Guard for the 6mg pre-filled syringes (procedure number EMEA/H/C/000420/IB/0067). Furthermore, the PI is being brought in line with the latest QRD template version 9.0. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data | 21/11/2013 | 13/11/2014 | SmPC, Annex II, Labelling and PL | The MAH implemented a pregnancy surveillance programme (PSP) and lactation surveillance programme (LSP) to facilitate the reporting of all available information on the use of Amgen products during pregnancy and lactation. This information has been included in the SmPC and PL to help increase awareness of the programmes among healthcare professionals. The MAH also updated the PI according to the latest QRD version 9.0. |
| IA/0073/G | This was an application for a group of variations. B.III.1.b.3 - Submission of a new/updated or deletion of Ph. Eur. TSE Certificate of Suitability - Updated certificate from an already approved                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 18/11/2013 | n/a        |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                       |

<div style=\"page-break-after: always\"></div>

|           | manufacturer B.III.1.b.3 - Submission of a new/updated or deletion of Ph. Eur. TSE Certificate of Suitability - Updated certificate from an already approved manufacturer                                                                                                                                                                                                                                                                                                          |            |            |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUV/0071 | Periodic Safety Update                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 19/09/2013 | 15/11/2013 | SmPC and PL | Update of section 4.4 of the SmPC to add a statement on traceability in line with other products in the class. The Package leaflet is updated accordingly. Please refer to: Neulasta-H-C-420-PSUV-0071 EPAR - Scientific conclusions and grounds recommending the variation to the terms of the marketing authorisation.                                                                                                                                                                                                                                                                                                                                                                                                       |
| IAIN/0069 | C.I.8.a - Introduction of or changes to a summary of Pharmacovigilance system - Changes in QPPV (including contact details) and/or changes in the PSMF location                                                                                                                                                                                                                                                                                                                    | 20/09/2013 | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| WS/0399   | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. Update of sections 4.4 and 4.8 of the SmPC to add capillary leak syndrome as a new adverse drug reaction and include a related warning further to the assessment of a signal by the PRAC. The Package Leaflet is updated accordingly. C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation | 25/07/2013 | 03/09/2013 | SmPC and PL | Capillary leak syndrome has been reported in recipients of granulocyte-colony stimulating factor (filgrastim and pegfilgrastim) including patients undergoing chemotherapy and a healthy donor undergoing peripheral blood progenitor cell mobilisation. It has been reported rarely in cancer patients undergoing chemotherapy following administration of Neulasta. Capillary leak syndrome is characterised by hypotension, hypoalbuminaemia, oedema and hemoconcentration. Patients who develop symptoms of capillary leak syndrome should be closely monitored and receive standard symptomatic treatment, which may include a need for intensive care. This information is reflected in the revised product information. |

<div style=\"page-break-after: always\"></div>

| IB/0067     | - Change of a measuring or administration - Other variation                                                                                                                                                                                                                                                                                                                                             | 02/08/2013   | 15/11/2013   | Labelling and PL   | B.IV.1.z device        |
|-------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|--------------------|------------------------|
| N/0068      | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                        | 15/07/2013   | 03/09/2013   | PL                 |                        |
| II/0065/G   | This was an application for a group of variations. to approve an alternative primary container closure system B.II.e.1.b.2 - Change in immediate packaging of the finished product - Type of container - Sterile medicinal products and biological/immunological medicinal products B.II.e.7.b - Change in supplier of packaging components or devices (when mentioned in the or addition of a supplier | 27/06/2013   | n/a          |                    | dossier) - Replacement |
| IB/0064     | B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure                                                                                                                                                                                                                                                                     | 23/04/2013   | n/a          |                    |                        |
| IAIN/0063   | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                                                          | 14/03/2013   | n/a          |                    |                        |
| IG/0247     | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                                                          | 14/12/2012   | n/a          |                    |                        |
| IAIN/0061/G | This was an application for a group of variations. B.II.b.1.a - Replacement or addition of a                                                                                                                                                                                                                                                                                                            | 29/11/2012   | 03/09/2013   | Annex II and PL    |                        |

<div style=\"page-break-after: always\"></div>

|         | manufacturing site for the FP - Secondary packaging site B.II.b.2.b.1 - Change to batch release arrangements and quality control testing of the FP - Not including batch control/testing                                                                                                                                                                                                                                                                |            |     |           |
|---------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-----------|
| IB/0060 | B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time data                                                                                                                                                                                                                                                                                  | 14/11/2012 | n/a |           |
| II/0058 | Introduction of a post approval change management protocol for the finished product. B.II.g.2 - Design Space - Introduction of a post approval change management protocol related to the finished product                                                                                                                                                                                                                                               | 18/10/2012 | n/a |           |
| IB/0059 | B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure                                                                                                                                                                                                                                                                                                                     | 11/09/2012 | n/a |           |
|         | This was an application for a group of variations. B.II.b.5.c - Change to in-process tests or limits applied during the manufacture of the finished product - Deletion of a non-significant in-process test B.II.b.5.a - Change to in-process tests or limits applied during the manufacture of the finished product - Tightening of in-process limits B.II.b.5.b - Change to in-process tests or limits applied during the manufacture of the finished | 08/08/2012 | n/a | IB/0057/G |

<div style=\"page-break-after: always\"></div>

|           | product - Addition of a new tests and limits B.II.b.5.c - Change to in-process tests or limits applied during the manufacture of the finished product - Deletion of a non-significant in-process test                                                                                                                                                                                                                                                                                                                                |            |            |    |           |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----|-----------|
| IA/0056/G | This was an application for a group of variations. B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS B.I.a.4.b - Change to in-process tests or limits applied during the manufacture of the AS - Addition of a new in-process test and limits B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process | 19/07/2012 | n/a        |    | of the AS |
| N/0053    | Update in the local representative details for Czech Republic, Denmark, Cyprus, Spain, Greece, Latvia, Netherlands, Poland and Portugal in the package leaflet. Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                     | 26/06/2012 | 03/09/2013 | PL |           |
| IA/0054   | A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 21/05/2012 | n/a        |    |           |

<div style=\"page-break-after: always\"></div>

| IB/0052   | - Change to batch release arrangements quality control testing of the FP - Replacement addition of a site where batch control/testing place                                                                                                                  | 14/03/2012   | n/a        |      | B.II.b.2.a and or takes   |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|------|---------------------------|
| IB/0051   | B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time data                                                                                       | 17/01/2012   | n/a        |      |                           |
| N/0050    | The MAH has updated the Package Leaflet to improve the instructions for injecting with Neulasta pre-filled syringe, with or without automatic needle guard. Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification) | 22/12/2011   | 25/05/2012 | PL   |                           |
| IB/0049   | B.I.b.1.c - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Addition of a new specification parameter to the specification with its corresponding test method                                        | 03/11/2011   | n/a        |      |                           |
| IB/0048   | B.II.f.1.b.5 - Stability of FP - Extension of the shelf life of the finished product - Extension of storage period of a biological/immunological medicinal product in accordance with an approved stability protocol                                         | 24/10/2011   | n/a        | SmPC |                           |
| IB/0047   | B.II.b.5.b - Change to in-process tests or limits applied during the manufacture of the finished a new tests and limits                                                                                                                                      | 15/09/2011   | n/a        |      | product - Addition of     |

<div style=\"page-break-after: always\"></div>

| II/0046   | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 14/04/2011   | 27/05/2011   | SmPC and PL   |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|---------------|
| WS/0043/G | This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. Changes in the manufacturing process, test procedures and specification parameters of the active substance. Change of specifications to comply with Ph. Eur. B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate B.III.2.a.2 - Change of specification(s) of a former non Pharmacopoeial substance to comply with the Ph. Eur. or with a national pharmacopoeia of a Member State - Excipient/AS starting material B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting | 16/12/2010   | 16/12/2010   |               |

<div style=\"page-break-after: always\"></div>

| B.I.b.1.z - Change in and/or limits of an AS, material/intermediate/reagent B.I.b.1.z - Change in and/or limits of an AS, material/intermediate/reagent B.I.b.1.c - Change in and/or limits of an AS, material/intermediate/reagent specification parameter corresponding test method B.I.b.1.b - Change in and/or limits of an AS, material/intermediate/reagent specification limits B.I.b.1.d - Change in and/or limits of an AS, material/intermediate/reagent significant specification an obsolete parameter) B.I.b.2.e - Change in starting material/reagent/intermediate changes to a test procedure or addition) for the AS material/intermediate B.I.b.2.e - Change in starting material/reagent/intermediate changes to a test procedure or addition) for the AS material/intermediate B.I.b.2.e - Change in   |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

|           | test procedure (including replacement or addition) for the AS or a starting material/intermediate A.4 - Administrative change - Change in the name and/or address of a manufacturer or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS                                                                                                                                                                                              |            |            |                        | changes to a          |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|-----------------------|
| IB/0045/G | This was an application for a group of variations. B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting | 16/12/2010 | n/a        |                        | material/intermediate |
| IB/0044   | Removal of the 'Sureclick' prefilled pen presentation (EU/1/02/227/003) from the approved list of presentations for Neulasta. Deletion of - a pharmaceutical form                                                                                                                                                                                                                                                                                                                    | 15/09/2010 | n/a        | SmPC, Labelling and PL | C.I.7.a -             |
| N/0043    | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                                     | 07/05/2010 | n/a        | Labelling and PL       |                       |
| II/0041   | Changes to the manufacturer of a starting material used in the manufacturing process for the active                                                                                                                                                                                                                                                                                                                                                                                  | 21/01/2010 | 02/02/2010 |                        |                       |

<div style=\"page-break-after: always\"></div>

|         | substance Change(s) to the manufacturing process for the active substance                                                                                                                                                                                                    |            |            |      |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
|---------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| N/0042  | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                             | 22/01/2010 | n/a        | PL   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| II/0040 | Upon request of the CHMP, the MAH submitted an update of the SPC sections 4.2, 4.8, 5.1 and 5.2 to add information for physicians on recommended use in paediatric patients based on a clinical study 990130 and a publication. Update of Summary of Product Characteristics | 24/09/2009 | 23/10/2009 | SmPC | The safety and efficacy data from study 990130 in paediatric patients lead to the amendment of section 4.2 and introduction of new information in sections 4.8, 5.1 and 5.2 of the SPC. Section 4.2 Paediatric patients The experience in children is limited. See sections 4.8, 5.1 and 5.2. Section 4.8 A higher frequency of serious adverse events in younger children aged 0-5 years (92%) has been observed compared to older children aged 6-11 and 12-21 years respectively (80% and 67%) and adults. The most common adverse study medicinal product reaction was bone pain (see section 5.1 and 5.2). Section 5.1 In a phase II (n = 37) multicentre, randomised, open-label study of paediatric sarcoma patients receiving 100 ?g/kg pegfilgrastim following cycle 1 of vincristine, doxorubicin and cyclophosphamide (VAdriaC/IE) chemotherapy, a longer duration of severe neutropenia (neutrophils < 0.5 x |

<div style=\"page-break-after: always\"></div>

|         |                                                                                             |            |            |                        | 109) was observed in younger children aged 0-5 yrs (8.9 days) compared to older children aged 6-11 years and 12- 21 years (6 days and 3.7 days, respectively) and adults. Additionally a higher incidence of febrile neutropenia was observed in younger children aged 0-5 yrs (75%) compared to older children aged 6 11 years and 12-21 years (70% and 33%, respectively) and adults (see sections 4.8 and 5.2). Section 5.2 Paediatric patients The pharmacokinetics of pegfilgrastim were studied in 37 paediatric patients with sarcoma, who received 100 ?g/kg pegfilgrastim after the completion of VAdriaC/IE chemotherapy. The youngest age group (0-5 years) had a higher mean exposure to pegfilgrastim (AUC) ( Standard Deviation) (47.9  22.5 ?ghr/ml) than older children aged 6-11 years and 12-21 years (22.0  13.1 ?ghr/ml and 29.3  23.2 ?ghr/ml, respectively) (see section 5.1). With the exception of the youngest age group (0 5 years), the mean AUC in paediatric subjects appeared similar to that for adult patients with high risk stage II-IV breast cancer and receiving 100 ?g/kg pegfilgrasti   |
|---------|---------------------------------------------------------------------------------------------|------------|------------|------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IA/0039 | IA_28_Change in any part of primary packaging material not in contact with finished product | 17/04/2009 | 17/04/2009 | SmPC, Labelling and PL |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| IB/0038 | IB_37_b_Change in the specification of the finished product - add. of new test parameter    | 14/08/2008 | n/a        |                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| II/0036 | Change(s) to the manufacturing process for the finished product                             | 30/05/2008 | 05/06/2008 |                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |

<div style=\"page-break-after: always\"></div>

| II/0037   | The MAH has applied to amend section 4.8 of the SPC to included information about the potential for elevated Liver Function Tests (LFTs) in patients treated with pegfilgrastim. Update of Summary of Product Characteristics                                                                   | 19/03/2008   | 21/04/2008   | SmPC        | The MAH has applied to amend section 4.8 of the SPC to included information about the potential for elevated Liver Function Tests (LFTs) in patients treated with pegfilgrastim.                                                                                               |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|-------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0035   | Change(s) to the manufacturing process for the active substance                                                                                                                                                                                                                                 | 21/02/2008   | 26/02/2008   |             |                                                                                                                                                                                                                                                                                |
| II/0034   | Update of Summary of Product Characteristics and Package Leaflet                                                                                                                                                                                                                                | 13/12/2007   | 17/01/2008   | SmPC and PL | Amendment to section 4.8 of the SPC with regard to the frequency of Sweet's syndrome. The Package Leaflet has also been amended accordingly.                                                                                                                                   |
| II/0033   | Change(s) to the manufacturing process for the active substance                                                                                                                                                                                                                                 | 15/11/2007   | 21/11/2007   |             |                                                                                                                                                                                                                                                                                |
| II/0032   | Update of Summary of Product Characteristics and Package Leaflet                                                                                                                                                                                                                                | 18/10/2007   | 20/11/2007   | SmPC and PL | Update of section 4.8 of the Summary of Product Characteristics to include: injection-site reactions, erythema and flushing. The package leaflet is updated accordingly. This variation fulfils a commitment made by the MAH which resulted from the recent renewal procedure. |
| II/0031   | Update of Summary of Product Characteristics to amend sections 4.2 and 5.2 with data from a study investigating the effects of renal impairment on the pharmacokinetics of pegfilgrastim. This variation fulfils a commitment made by the MAH which resulted from the recent renewal procedure. | 18/10/2007   | 20/11/2007   | SmPC        |                                                                                                                                                                                                                                                                                |

<div style=\"page-break-after: always\"></div>

| R/0030   | Renewal of the marketing authorisation.                                                          | 24/05/2007   | 16/07/2007   |                                  |                                                                                                                                                                                                                                                                                                                                                                             |
|----------|--------------------------------------------------------------------------------------------------|--------------|--------------|----------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0029  | Change(s) to the manufacturing process for the finished product                                  | 22/03/2007   | 27/03/2007   |                                  |                                                                                                                                                                                                                                                                                                                                                                             |
| II/0028  | Change to the test procedure and/or specification of a raw material                              | 22/03/2007   | 27/03/2007   |                                  |                                                                                                                                                                                                                                                                                                                                                                             |
| II/0027  | Change(s) to the manufacturing process for the active substance                                  | 24/01/2007   | 29/01/2007   |                                  |                                                                                                                                                                                                                                                                                                                                                                             |
| II/0026  | Update of Summary of Product Characteristics and Package Leaflet                                 | 16/11/2006   | 03/01/2007   | SmPC, Annex II, Labelling and PL | Update to sections 4.4 and 4.8 of the SPC following a review of the Company Core Data Sheet and a recent assessment of the 7th PSUR. Update to sections 2 and 4 of the Package Leaflet with regards to information on allergy to latex and very rare events of cutaneous vasculitis. Update to section 6 of the Package Leaflet on how to administer the medicinal product. |
| II/0025  | Change(s) to the manufacturing process for the active substance                                  | 27/07/2006   | 18/08/2006   |                                  |                                                                                                                                                                                                                                                                                                                                                                             |
| II/0023  | Change(s) to the manufacturing process for the active substance                                  | 27/04/2006   | 03/05/2006   |                                  |                                                                                                                                                                                                                                                                                                                                                                             |
| IA/0024  | IA_38_a_Change in test procedure of finished product - minor change to approved test procedure   | 17/01/2006   | n/a          |                                  |                                                                                                                                                                                                                                                                                                                                                                             |
| IB/0022  | IB_37_a_Change in the specification of the finished product - tightening of specification limits | 10/01/2006   | n/a          |                                  |                                                                                                                                                                                                                                                                                                                                                                             |
| II/0020  | The Marketing Authorisation Holder applied to add a                                              | 15/09/2005   | 28/10/2005   | SmPC,                            |                                                                                                                                                                                                                                                                                                                                                                             |

<div style=\"page-break-after: always\"></div>

|         | new prefilled pen presentation to the product range. New presentation(s)                                                                                                               |            |            | Labelling and PL   |                                                                                                                                                                                                                                                                          |
|---------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|--------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0015 | Sections 4.8 and 5.1 of the SPC were updated to reflect new data on the use of Neulasta in patients with de novo acute myeloid leukaemia. Update of Summary of Product Characteristics | 15/09/2005 | 28/10/2005 | SmPC               | Sections 4.8 and 5.1 of the SPC were updated to reflect new data on the use of Neulasta in patients with de novo acute myeloid leukaemia.                                                                                                                                |
| II/0018 | Change(s) to the manufacturing process for the active substance                                                                                                                        | 27/07/2005 | 31/08/2005 | Annex II           |                                                                                                                                                                                                                                                                          |
| II/0019 | Update of Summary of Product Characteristics and Package Leaflet                                                                                                                       | 23/06/2005 | 01/08/2005 | SmPC and PL        | Sections 4.4 and 4.8 of the SPC were amended to update the safety information in relation to pulmonary effects and to add \"leucocytosis\" further to the assessment of the 5th PSUR. The Patient Leaflet was amended accordingly.                                         |
| IA/0021 | IA_28_Change in any part of primary packaging material not in contact with finished product                                                                                            | 29/06/2005 | n/a        |                    |                                                                                                                                                                                                                                                                          |
| II/0017 | Update of Summary of Product Characteristics                                                                                                                                           | 16/03/2005 | 29/04/2005 | SmPC               | Sections 4.8 and 5.1 of the SPC were amended to reflect the results from a phase 3 study showing that the addition of pegfilgrastim to docetaxel in patients with breast cancer had a beneficial effect on the primary endpoint of the incidence of febrile neutropenia. |
| II/0016 | The Marketing Authorisation Holder applied to update the manufacturing process for the active substance. Quality changes                                                               | 16/03/2005 | 21/03/2005 |                    |                                                                                                                                                                                                                                                                          |

<div style=\"page-break-after: always\"></div>

| II/0014   | The Marketing Authorisation Holder applied to change the active substance and product specifications.                                                                               | 16/03/2005   | 21/03/2005   |                        | Quality changes   |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|------------------------|-------------------|
| II/0013   | Update of Summary of Product Characteristics and Package Leaflet                                                                                                                    | 15/12/2004   | 25/01/2005   | SmPC and PL            |                   |
| IB/0012   | IB_12_b_02_Change in spec. of active subst./agent in manuf. of active subst. - test parameter                                                                                       | 09/08/2004   | n/a          |                        |                   |
| II/0007   | Change(s) to the manufacturing process for the active substance                                                                                                                     | 29/07/2004   | 02/08/2004   |                        |                   |
| IB/0010   | IB_42_a_01_Change in shelf-life of finished product - as packaged for sale                                                                                                          | 01/07/2004   | n/a          | SmPC and PL            |                   |
| II/0009   | Change(s) to the manufacturing process for the finished product                                                                                                                     | 23/06/2004   | 29/06/2004   |                        |                   |
| II/0008   | Change(s) to shelf-life or storage conditions                                                                                                                                       | 23/06/2004   | 23/06/2004   |                        |                   |
| IA/0011   | IA_28_Change in any part of primary packaging material not in contact with finished product IA_41_a_01_Change in pack size - change in no. of units within range of appr. pack size | 18/06/2004   | 18/06/2004   | SmPC, Labelling and PL |                   |
| II/0004   | Change(s) to the manufacturing process for the active substance                                                                                                                     | 22/04/2004   | 27/04/2004   |                        |                   |

<div style=\"page-break-after: always\"></div>

| II/0002   | Update of Summary of Product Characteristics and Package Leaflet                                                           | 20/11/2003   | 29/01/2004   | SmPC and PL   |
|-----------|----------------------------------------------------------------------------------------------------------------------------|--------------|--------------|---------------|
| II/0003   | Change(s) to the manufacturing process for the active substance                                                            | 17/12/2003   | 15/01/2004   |               |
| II/0001   | Update of or change(s) to the pharmaceutical documentation Change(s) to the manufacturing process for the active substance | 22/05/2003   | 02/06/2003   |               |